24th week of 2020 patent applcation highlights part 10 |
Patent application number | Title | Published |
20200179358 | COMPOUNDS AND THEIR METHODS OF USE - The present invention is directed to, in part, fused heteroaryl compounds and compositions useful for preventing and/or treating a disease or condition relating to aberrant function of a voltage-gated, sodium ion channel, for example, abnormal late/persistent sodium current. Methods of treating a disease or condition relating to aberrant function of a sodium ion channel including neurological disorders (e.g., Dravet syndrome, epilepsy), pain, and neuromuscular disorders are also provided herein. | 2020-06-11 |
20200179359 | METHODS OF TREATING PANCREATIC CANCER - The present disclosure describes methods of treating pancreatic cancer and limiting over-expression of oncogenes, activating tumor suppressor genes or regulating signaling proteins in patients comprising administering compounds and pharmaceutical combinations as described herein. | 2020-06-11 |
20200179360 | DEUTERIUM-ENRICHED PIOGLITAZONE - The present application describes deuterium-enriched pioglitazone, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2020-06-11 |
20200179361 | COMPOSITIONS, METHODS OF USE, AND METHODS OF TREATMENT - The present disclosure provides compositions including a α4β2 nAChR antagonist, pharmaceutical compositions including a α4β2 nAChR antagonist, methods of making the compositions or pharmaceutical compositions, methods of treatment of a condition (e.g., nicotine addiction) or disease, methods of treatment using compositions or pharmaceutical compositions, and the like. Embodiments of the present disclosure can be used to reduce nicotine cravings and treat nicotine addiction. The compositions have selective affinity for the α4β2 receptor, which appears to be involved in nicotine dependence. | 2020-06-11 |
20200179362 | DIETARY SUPPLEMENT COMPRISING GLUCURONIDATION INHIBITION ASSIST FOR HEALTHFUL DAILY SYNERGY OF ANTI-INFLAMMATION, CELLULAR ANTI-OXIDANT BOOST, CELLULAR PROTEIN CLEAN-UP BOOST - The present invention comprises a method and system for configuring a dietary supplement and providing same to user, linked to publically accessible notice at least referencing partial autophagy effect. Said dietary supplement can be configured as tablet, capsule, liquid aliquot, powder, pill, food additive or other common or uncommon forms of dietary supplement. Said dietary supplement comprises in recommended daily dose over years, as a majority of milligrams of active ingredients: at least one component to reduce inflammation, at least one component to boost local cellular production of antioxidants, at least one component to boost local cellular clean-up of damaged protein, at least one component to inhibit glucuronidation. | 2020-06-11 |
20200179363 | METHODS FOR TREATING NASH AND FOR PREVENTING NASH-INDUCED HCC - Disclosed are methods of treating non-alcoholic steatohepatitis (NASH) and methods of preventing NASH-induced hepatocellular carcinoma (HCC), such methods including administering O-(3-piperidino-2-hydroxy-1-propyl)-nicotinic amidoxime (BGP15), alone or in combination with a inhibitor of the interleukin-6 receptor transsignaling response, particularly gp130Fc. | 2020-06-11 |
20200179364 | LOW DOSE COMBINATION THERAPY FOR TREATMENT OF MYELOPROLIFERATIVE NEOPLASMS - The present application relates to treatment of myeloproliferative neoplasms using the JAK1/JAK2 inhibitor, ruxolitinib, in combination with a low dose of a Pim inhibitor, N-{(7R)-4-[(3R,4R,5S)-3-amino-4-hydroxy-5-methylpiperidin-1-yl]-7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-3-yl}-6-(2,6-difluorophenyl)-5-fluoropyridine-2-carboxamide, wherein the combination is unexpectedly synergistic at a very low dose of the Pim inhibitor. | 2020-06-11 |
20200179365 | Method of Regulating Tumor Necrosis Factor-alpha (TNF-alpha) for Treating Cancers, Autoimmune Disorders, and Other Disorders Associated with Chronic Inflammation - In one aspect, a method of treating a disorder associated with chronic inflammation includes administering to an individual in need thereof a therapeutically effective amount of isomyosmine or a pharmaceutically acceptable salt thereof. In some aspects, the disorder is a cancer, an autoimmune disorder, hypertension, or autism. In other aspects, isomyosmine is administered to treat viral infections or disorders associated with elevated levels of hydrogen peroxide and/or other Reactive Oxygen Species (ROS). | 2020-06-11 |
20200179366 | METHOD OF TREATING VIRAL INFECTIONS - In one aspect, a method of treating a disorder associated with chronic inflammation includes administering to an individual in need thereof a therapeutically effective amount of isomyosmine or a pharmaceutically acceptable salt thereof. In some aspects, the disorder is a cancer, an autoimmune disorder, hypertension, or autism. In other aspects, isomyosmine is administered to treat viral infections or disorders associated with elevated levels of hydrogen peroxide and/or other Reactive Oxygen Species (ROS). | 2020-06-11 |
20200179367 | Method of Treating Coronavirus - In one aspect, a coronavirus is treated by administering a pharmaceutical composition containing a therapeutically effective amount of isomyosmine or a pharmaceutically acceptable salt thereof. In another aspect, oxidative stress is reduced in an individual suffering from a coronavirus by administering a pharmaceutical composition containing a therapeutically effective amount of isomyosmine or a pharmaceutically acceptable salt thereof. In another aspect, mitochondrial reactive oxygen species (mtROS) are inhibited in an individual suffering from a coronavirus by administering a pharmaceutical composition containing a therapeutically effective amount of isomyosmine or a pharmaceutically acceptable salt thereof. In one example, the coronavirus is Covid-19. | 2020-06-11 |
20200179368 | USE OF NEURONAL NITRIC OXIDE SYNTHASE INHIBITORS FOR IMMUNOTHERAPY IN MELANOMA PATIENTS - Disclosed herein are methods and compositions for administering immunotherapy to a subject in need thereof and for treating a subject in need thereof, where in the methods the subject is administered an effective amount of an inhibitor of nNOS for inducing an immunotherapeutic response in the subject and for treating the subject. The disclosed methods and composition may be utilized for treating a subject having a cell proliferative disease or disorder such as melanoma. | 2020-06-11 |
20200179369 | TREATMENT OF DIABETIC NEPHROPATHY - The present invention is directed to the treatment of diabetic nephropathy with a) a phosphodiesterase 4 inhibitor, b) a combination of a phosphodiesterase 4 inhibitor with an AT | 2020-06-11 |
20200179370 | TREATMENT OF EPILEPSY - The present invention discloses isoquinolines and 1H-2-Benzopyranes and their use in the treatment and prevention in epilepsy and other seizures. The present invention further discloses methods to screen isoquinoline- and 1H-2-Benzopyran-like molecules as pharmaceutically active compounds. | 2020-06-11 |
20200179371 | Stabilizing Camptothecin Pharmaceutical Compositions - Irinotecan phospholipid liposomes with improved storage stability are provided, with related methods of treatment and manufacture. The irinotecan liposomes can have reduced formation of lyso-phosphatidylcholine (lyso-PC) during storage, and prior to administration to a patient. | 2020-06-11 |
20200179372 | PHARMACEUTICAL FORMULATIONS FOR SUSTAINED RELEASE OF SEBACOYL DINALBUPHINE ESTER - The present invention relates to injectable, extended-release, pharmaceutical formulations comprising a nalbuphine ester prodrug homogenously dissolved in a solution comprising a pharmaceutically acceptable oil and an oil-miscible retaining solvent, as well as manufacturing processes and medical uses of the formulations. The invention further provides methods for adjusting the duration of action of the formulations by varying the ratio of the pharmaceutically acceptable oil and the oil-miscible retaining solvent. | 2020-06-11 |
20200179373 | PHARMACEUTICAL FORMULATIONS FOR SUSTAINED RELEASE OF SEBACOYL DINALBUPHINE ESTER - The present invention relates to injectable, extended-release, pharmaceutical formulations comprising a nalbuphine ester prodrug homogenously dissolved in a solution comprising a pharmaceutically acceptable oil and an oil-miscible retaining solvent, as well as manufacturing processes and medical uses of the formulations. The invention further provides methods for adjusting the duration of action of the formulations by varying the ratio of the pharmaceutically acceptable oil and the oil-miscible retaining solvent. | 2020-06-11 |
20200179374 | METHODS AND COMPOSITIONS FOR REDUCING TACTILE DYSFUNCTION AND ANXIETY ASSOCIATED WITH AUTISM SPECTRUM DISORDER, RETT SYNDROME, AND FRAGILE X SYNDROME - The present invention features a method of reducing tactile dysfunction or anxiety in a subject diagnosed with Autism Spectrum Disorder, Rett Syndrome, or Fragile X syndrome by administering a GABA | 2020-06-11 |
20200179375 | FORMULATIONS OF OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES - The invention relates to a pharmaceutical composition comprising a protein phosphatase 2A (PP2A) inhibitor and monosodium glutamate. | 2020-06-11 |
20200179376 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING INHIBITORY EFFECT ON PRODUCTION OF KYNURENINE - The present invention provides a nitrogen-containing heterocyclic compound or a pharmaceutically acceptable salt thereof having an inhibitory effect on the production of kynurenine, represented by formula (I): | 2020-06-11 |
20200179377 | CERTAIN TRIAZOLOPYRIDINES AND TRIAZOLOPYRAZINES, COMPOSITIONS THEREOF AND METHODS OF USE THEREFOR - Provided are certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use therefor. | 2020-06-11 |
20200179378 | Compositions, Devices, and Methods for Treating or Preventing Headaches - Disclosed herein are pharmaceutical compositions, devices, their combinations, and their uses thereof for example in treating or preventing headaches. | 2020-06-11 |
20200179379 | INTRANASAL DHE FOR THE TREATMENT OF HEADACHE - Presented herein are powder formulations comprising dihydroergotamine (DHE), or a pharmaceutically acceptable salt thereof. In addition to such formulations, also presented herein are methods comprising intranasally administering powder formulations comprising dihydroergotamine, or a pharmaceutically acceptable salt thereof. The presented methods can be used for treating headache, for example, for rapid onset treatment of headache, including migraine, e.g. acute treatment of migraine with or without aura. | 2020-06-11 |
20200179380 | SOLUTE AND SOLUTE MIXTURE, AS WELL AS A COMPOSITION COMPRISING AT LEAST ONE SOLUTE, FOR USE IN THE PREVENTION OR TREATMENT OF COSMETIC OR PATHOLOGIC EFFLORESCENCES CAUSED BY AIRBORNE PARTICLES - The invention relates to a compatible solute or a solute mixture, as well as to a composition comprising the solute or solute mixture, for use in the prevention or treatment of cosmetic or pathologic efflorescences caused by airborne particles, such as pigmentation accompanying with skin ageing, and de- or hypopigmentation, hyperpigmentation, as well as alterations accompanying with atrophy in the broadest sense. The solute or solute mixture, as well as the composition comprising the solute or solute mixture comprises at least one compound according to formula I, formula II, physiologically compatible salts of formula I and formula II, stereoisomeric forms of the compound of formula I, formula II, and physiologically compatible salts of the stereoisomeric forms, and the solute mixture comprises at least two of the afore-mentioned compounds, wherein in formula I | 2020-06-11 |
20200179381 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OR PREVENTION OF PATHOLOGICAL CONDITIONS ASSOCIATED WITH EXCESS FIBRIN DEPOSITION AND/OR THROMBUS FORMATION - There is herein provided an HDAC inhibitor, or a pharmaceutically acceptable salt thereof, as described in the description, for use in treating or preventing a pathological condition associated with excess fibrin deposition and/or thrombus formation, wherein said treatment comprises treating a patient with an HDAC inhibitor, or a pharmaceutically acceptable salt thereof, in a specific manner, and formulations for use or designed for use in such treatments. | 2020-06-11 |
20200179382 | METHODS OF TREATING CIRCADIAN RHYTHM SLEEP DISORDERS - Methods of treating irregular sleep-wake rhythm disorder in subjects and compositions for use in the same are disclosed. | 2020-06-11 |
20200179383 | PHENYL DERIVATIVES AS PGE2 RECEPTOR MODULATORS - The present invention relates to phenyl derivatives of formula (I) | 2020-06-11 |
20200179384 | N2,N4-DIPHENYLPYRIMIDINE-2,4-DIAMINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF CANCER - The present invention relates to a N2,N4-diphenylpyrimidin-2,4-diamine derivative, a method for preparing the same, and a pharmaceutical composition for the prevention or treatment of cancer, containing the same as an active ingredient. The derivative shows a relatively weak EGFR activity inhibitory effect on wild-type EGFR, a high inhibitory ability on EGFR mutation, and a high inhibitory ability on even FLT3 and FLT3 mutation, and thus, can be effectively used for the treatment of cancer with EGFR mutation or cancer with FLT3 or a mutation thereof, and the derivative shows a synergy effect at the time of combination administration, and thus can be effectively used for the treatment of combination administration. | 2020-06-11 |
20200179385 | NOVEL COMPOUNDS - The invention provides compounds of formula (I): | 2020-06-11 |
20200179386 | METOLAZONE EMULSION FORMULATION - The present invention relates to pharmaceutical formulations comprising metolazone, a lipid, and an emulsifier that provide a lipid formulation of metolazone that can be administered intravenously to patients, thereby enhancing the therapeutic delivery and improving patient care for acute heart failure and resistant edmitious states. | 2020-06-11 |
20200179387 | USES OF SALT-INDUCIBLE KINASE (SIK) INHIBITORS FOR TREATING OSTEOPOROSIS - The present disclosure provides methods of treating and/or preventing osteoporosis using salt-inducible kinase (SIK) inhibitors. Also provided are methods of using SIK inhibitors for increasing the function of osteocytes, increasing the number of osteoblasts, increasing the activity of osteoblasts, inhibiting the resorption of a bone, decreasing the number of osteoclasts, inhibiting the activity of osteoclasts, increasing the mass of a bone, down-regulating the expression of the gene SOST, and/or inhibiting the activity of sclerostin. The SIK inhibitors may be combined with Src inhibitors or CSF I R inhibitors. Exemplary SIK inhibitors include the compounds of the formula: (I), (II), (III), (IV), (V) or (VI). | 2020-06-11 |
20200179388 | VASODILATORS FOR TREATMENT OF HEART FAILURE - A method for treating or preventing heart failure involving blockage of small blood vessels is described. The method involves administering to a subject in need thereof a therapeutically effective amount of a vasodilator. | 2020-06-11 |
20200179389 | NOVEL ALK2 INHIBITORS AND METHODS FOR INHIBITING BMP SIGNALING - The present invention provides small-molecule inhibitors of BMP signaling and compositions and methods for inhibiting BMP signaling. These compounds and compositions may be used to modulate cell growth, differentiation, proliferation, and apoptosis, and thus may be useful for treating diseases or conditions associated with BMP signaling, including inflammation, cardiovascular disease, hematological disease, cancer, and bone disorders, as well as for modulating cellular differentiation and/or proliferation. These compounds and compositions may also be used to treat subjects with Sjögren's syndrome, or diffuse intrinsic pontine glioma (DIPG). | 2020-06-11 |
20200179390 | GONADOTROPIN-RELEASING HORMONE ANTAGONIST DOSING REGIMENS FOR TREATING UTERINE FIBROIDS AND REDUCING MENSTRUAL BLOOD LOSS - The invention provides compositions and methods for reducing the volume of menstrual blood loss in a patient, such as a human patient, for instance, that has uterine fibroids, by administration of a gonadotropin-releasing hormone (GnRH) antagonist. Suitable GnRH antagonists useful in conjunction with the compositions and methods described herein include thieno[3,4d]pyrimidine derivatives, such as 3-[2-fluoro-5-(2,3-difluoro-6-methoxybenzyloxy)-4-methoxypheny I]-2,4-dioxo-1,2,3,4-tetrahydrothieno[3,4d]pyrimidine-5-carboxylic acid and the choline salt thereof. | 2020-06-11 |
20200179391 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES - The present invention provides compounds of Formula A: | 2020-06-11 |
20200179392 | Idelalisib for Treating Proliferative Vitreoretinopathy and Abnormal Intraocular Neovascularization - Methods using idelalisib to treat proliferative vitreoretinopathy and intraocular pathological angiogenesis (e.g., proliferative diabetic retinopathy (PDR), retinopathy of prematurity (ROP), and wet age-related macular degeneration (AMD)). | 2020-06-11 |
20200179393 | COMPOSITIONS AND METHODS FOR AMELIORATING PAIN - This invention is directed to compositions, methods and kits that can be used for the treatment or amelioration of pain. | 2020-06-11 |
20200179394 | Compounds that Enhance Atoh1 Expression - This invention generally provides compounds, pharmaceutical compositions, and methods for their use, which include methods that result in increased expression in an Atoh1 gene (e.g., Hath1) in a biological cell. More specifically, the invention relates to the treatment of diseases and/or disorders that would benefit from increased Atoh1 expression, e.g., a hearing impairment or imbalance disorder associated with a loss of auditory hair cells, or a disorder associated with abnormal cellular proliferation. | 2020-06-11 |
20200179395 | PHARMACEUTICAL COMPOSITIONS - Pharmaceutical compositions and methods are provided to treat headache, headache-associated symptoms, photophobia, or adverse effects associated with triptan administration. | 2020-06-11 |
20200179396 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM - Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a T | 2020-06-11 |
20200179397 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF HEARING LOSS - In one aspect, pharmaceutical compositions comprising a CDK2 inhibitor and one or more of at least one agent known to treat a hearing impairment and at least one agent known to prevent a hearing impairment, and methods of treating and/or preventing hearing impairments or disorders using the compositions are disclosed. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention. | 2020-06-11 |
20200179398 | CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES FOR TREATING BRONCHIECTASIS - The present disclosure relates to methods for treating bronchiectasis, for example, non-cystic fibrosis bronchiectasis with compositions comprising an effective amount of certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamide compounds of Formula (I), including pharmaceutically acceptable salts thereof, | 2020-06-11 |
20200179399 | ORAL QUETIAPINE SUSPENSION FORMULATIONS WITH EXTENDED SHELF LIFE AND ENHANCED BIOAVAILABILITY - A quetiapine fumarate composition for oral administration is provided comprising a pharmaceutically acceptable salt or solvate of quetiapine existing as a suspension in an aqueous carrier agent. The inventive liquid formulation demonstrates high bioavailability consistent with approved dosage forms, low agglomeration, reduced content of excipients commonly used in solid oral dosage forms and extended shelf life stability. Also provided is a method of manufacturing a liquid quetiapine suspension composition for oral administration and methods of administering therapeutically effective dosages of an oral liquid quetiapine suspension composition to patients in need thereof. | 2020-06-11 |
20200179400 | COMPOSITION CONTAINING SULFOALKYL ETHER CYCLODEXTRIN AND LATANOPROST - An aqueous composition of latanoprost and SAE-CD is provided. The composition possesses improved stability over otherwise similar compositions excluding SAE-CD. Methods of and systems for treating disease, disorders, conditions or symptoms of the eye that are therapeutically responsive to latanoprost are also provided. | 2020-06-11 |
20200179401 | NITRIC OXIDE RELEASING PROSTAGLANDIN DERIVATIVES FOR TREATING NORMAL TENSION GLAUCOMA - This invention provides a method of lowering intraocular pressure in a patient having normal tension glaucoma, comprising contacting an eye of a subject having normal tension glaucoma with a pharmaceutical composition comprising an effective amount of Nitric Oxide releasing prostaglandin derivatives of formula (I). | 2020-06-11 |
20200179402 | MONOHYDROXYLATED 17ALPHA-HYDROXYPROGESTERONE CAPROATE FOR REDUCING CONTRACTILITY - A monohydroxylated 17α-hydroxyprogesterone caproate (HPC—OH), 17α-hydroxyprogesteryl 6-hydroxycaproate, is disclosed herein for reducing uterine contractions, reducing inflammation related to contractility, and preventing preterm birth. Additionally, the use of HPC—OH as a diagnostic is also disclosed. | 2020-06-11 |
20200179403 | GANAXOLONE FOR USE IN PROPHYLAXIS AND TREATMENT OF POSPARTUM DEPRESSION - Uses of ganaxolone in prophylaxis and treatment of postpartum depression are described. A dose of ganaxolone is administered to a female suffering from postpartum depression or at risk of developing postpartum depression in an amount and at a rate sufficient to alleviate at least one symptom of postpartum depression in the female. | 2020-06-11 |
20200179404 | SKIN CARE FORMULATIONS AND SKIN CANCER TREATMENT - An example technique for treating a skin cancer condition includes administering a therapeutically effective amount of a p53-related protein kinase (PRPK) inhibitor to a patient having skin cancer or having a high risk of developing skin cancer. An example composition includes a therapeutically effective amount of a PRPK inhibitor for treating a skin cancer condition. An example composition includes a pharmaceutically effective amount of at least one anti-solar ultraviolet (anti-sUV) combination for preventing a skin cancer condition. The at least one anti-sUV combination is chosen from the combinations: avobenzone and octinoxate; octocrylene and zinc oxide; avobenzone, octocrylene, and titanium dioxide; or avobenzone, octocrylene, and zinc oxide. | 2020-06-11 |
20200179405 | DERMATOLOGICAL COMPOSITIONS AND METHODS - Dermatological compositions (methods of making and using) that include one or more anesthetic agents and/or one or more anti-inflammatory agents and/or a combination of ammonium, sodium, and potassium salts, preferably of an alpha-hydroxy acid. | 2020-06-11 |
20200179406 | INJECTABLE LONG-ACTING SEMI-SOLID GEL FORMULATIONS - What is disclosed is a controlled release pharmaceutical composition comprising a biocompatible and bioerodible semi-solid gel comprising a mixture of a triglyceride of ricinoleic acid and a gelling agent, in a formulation with loteprednol, latanoprost, celecoxib, triamcinolone, or betamethasone and, optionally, a second corticosteroid, analgesic, or anti-inflammatory agent. | 2020-06-11 |
20200179407 | USE OF 20-HYDROXYECDYSONE AND THE DERIVATIVES THEREOF IN THE TREATMENT OF MYOPATHIES - The invention relates to 20-hydroxyecdysone and the derivatives thereof, for use in the treatment of genetic myopathies. | 2020-06-11 |
20200179408 | INHIBITION OF CATALYTIC SITE COMMON TO MULTIPLE 3 ALPHA-OXIDOREDUCTASES FOR TREATMENT OF PROSTATE CANCER - Methods and compositions which are directed against catalytic site common to multiple 3 alpha-oxidoreductases. The compositions can be used for the treatment of prostate cancer. | 2020-06-11 |
20200179409 | TOPICAL COMPOSITIONS AND METHODS OF FORMULATING THE SAME - A topical composition may include one or more pharmaceutical drugs in a moisturizing ointment including PEG-8 and PEG-75, water, Spiraea ulmaria flower extract, zinc acetate, and propylene glycol. The topical composition may be administered to skin, a vagina, a nasal passage, or an anal cavity of a mammal. | 2020-06-11 |
20200179410 | VITAMIN D COMPOUNDS AND METHODS OF USING THE SAME - The present disclosure provides a composition comprising a first amount of a Vitamin D compound and a second amount of a probiotic compound. The disclosure also provides a method of treating an atopic condition in a subject in need thereof comprising administering to the subject a therapeutically effective amount of the composition detailed herein. | 2020-06-11 |
20200179411 | PHARMACEUTICAL SUSPENSIONS FOR BISMUTH SUBSALICYLATES - The invention is directed to pharmaceutical compositions for suspending bismuth subsalicylate and methods of use thereof. Formulations of the present invention include at least three-gum systems to prevent the settling out of heavy particles in solution and do not include magnesium aluminum silicate. The pharmaceutical compositions may be used to treat gastrointestinal disorders. | 2020-06-11 |
20200179412 | COMPOSITIONS FOR THE TREATMENT OF FIBROSIS - The present disclosure is directed to methods of treating fibrotic conditions by administration of TRβ agonists. The disclosure provides methods wherein the abnormal deposition of extracellular matrix components, such as collagen, keratin, or elastin, is reduced, either through interaction of TRβ agonists with TGF-β-dependent inflammatory pathways, or by other mechanisms, thereby ameliorating fibrotic symptoms. | 2020-06-11 |
20200179413 | Surfactant Lipids, Compositions Thereof, and Uses Thereof - The invention generally relates to methods to inhibit inflammation or pathogen infection by administering at least one anionic lipid or compositions comprising at least one anionic lipid to an individual. The invention also relates to methods to prevent or inhibit respiratory syncytial virus (RSV) infection by administering at least one anionic lipid or compositions comprising at least one anionic lipid to an individual. The invention further relates to compositions comprising randomly mixed surfactant lipids and methods to produce the compositions. | 2020-06-11 |
20200179414 | COMPOSITION FOR TREATMENT AND/OR PREVENTION OF ALZHEIMER'S DISEASE - Provided is a composition for the treatment and/or prevention of Alzheimer's disease having an improved therapeutic or prophylactic effect together with reduced side effects. This composition for the treatment and/or prevention of Alzheimer's disease contains at least one compound selected from the group consisting of glycerophosphocholine (G) and pharmaceutically acceptable salts thereof as a first active ingredient and at least one compound selected from the group consisting of herperidin (H), narirutin (N), and pharmaceutically acceptable salts thereof as a second active ingredient. This composition promotes remyelination, promotes the activity of α-secretase, and also suppresses the expression of β-secretase. | 2020-06-11 |
20200179415 | HIGHLY ACTIVE DRUG COMBINATION FOR TREATMENT OF HEPATITIS C VIRUS - A combination is provided of Compound 1 or a pharmaceutically acceptable salt thereof (such as Compound 1-A) and Compound 2 or a pharmaceutically acceptable salt thereof (such as Compound 2-A) | 2020-06-11 |
20200179416 | ANTI-INFLAMMATORY PROPERTIES OF MARINE LIPID COMPOSITIONS - Novel marine lipid compositions comprising triglycerides and omega-3 rich phospholipids are described. The compositions are characterized by providing highly bioavailable omega-3, increased tissue incorporation of omega-3 and reduced concentration of pro-inflammatory cytokines. | 2020-06-11 |
20200179417 | COMBINATION CHEMOTHERAPIES - Combination of agents that increase the amount of reactive oxygen species with agents that are activated, enhanced, or induced by oxygen species for the treatment of cancer and pre-cancerous disease. Pharmaceutical compositions comprising a therapeutic agent or drug that generate or produce reactive oxygen species (ROS) in a disease microenvironment, and at least one drug or agent that is activated, enhanced, or induced by ROS for the treatment of mammalian cancer, dysplastic disorders, neoplastic, or hyperproliferative disorders and methods of using thereof for the treatment of mammalian cancer dysplastic disorders, neoplastic, or hyperproliferative disorders. | 2020-06-11 |
20200179418 | BORON CONTAINING SMALL MOLECULES AS ANTI-INFLAMMATORY AGENTS - Methods of treating anti-inflammatory conditions through the use of boron-containing small molecules are disclosed. | 2020-06-11 |
20200179419 | METHOD FOR THE MANUFACTURE AND USE OF A BIONIC HYDROGEL COMPOSITION FOR MEDICAL APPLICATIONS - The invention relates to a method for the stabilization of a polysaccharide (hyaluronic acid) with a biomolecule—amino acid—through crosslinking, to generate a bionic hydrogel based on physiological building blocks for applications in regenerative medicine. The designed biosimilar hydrogel is intended to be used in regenerative medicine for the purpose of regenerate, rejuvenate and/or restore the structure or function of impaired or damaged tissues, and to promote healing. The manufacture method is composed of a single step that includes mixing L-lysine and hyaluronic acid sodium salt in an aqueous saline solution with either EDC/NHS as coupling agent. | 2020-06-11 |
20200179420 | HDAC INHIBITOR COMPOSITIONS FOR REACTIVATION OF THE X CHROMOSOME - A reactivation composition for activating or re-activating expression of a silenced X chromosome gene in a cell includes a non-cytotoxic histone deacetylase (HDAC) inhibitor. The reactivation composition includes the non-cytotoxic HDAC inhibitor and may further include a DNA methylation inhibitor. A method of activating or re-activating expression of a silenced X chromosome gene in a cell includes administering a reactivation composition including a non-cytotoxic HDAC inhibitor. The method of activating or re-activating expression of a silenced X chromosome gene may further includes administering a reactivation composition that includes a non-cytotoxic HDAC inhibitor and an inhibitor of DNA methylation. | 2020-06-11 |
20200179421 | Methods and Compositions for Preventing and Treating Conditions Related to Alpha-Synuclein - Provided herein are methods of treating constipation in subjects in need thereof. The method includes administering a therapeutically effective dosage of N-acetylglucosamine. Subjects who may benefit from treatment include those having synucleinopathies, including Parkinson's Disease. | 2020-06-11 |
20200179422 | IP AND IP ANALOGS DOSAGE REGIMENS FOR THE TREATMENT OF ECTOPIC CALCIFICATIONS - The present disclosure related to compositions, methods, dosages, dosage regimens, articles of manufacture and kits for the treatment and/or prevention ectopic calcifications, and in particular cutaneous calcifications such as calciphylaxis calcifications comprising inositol phosphate, inositol phosphate analogs, inositol phosphate derivatives, or combinations thereof. In a particular aspect the disclosure provides a dosage regimen to treat calciphylaxis comprising the administration of 6 mg/kg to 9 mg/kg daily doses of myo-inositol hexaphosphate, three times a week, for at least 1 to 8 months. | 2020-06-11 |
20200179423 | USE OF SECOISOLARICIRESINOL DIGLUCOSIDES (SDGS) AND RELATED COMPOUNDS FOR PROTECTION AGAINST RADIATION AND CHEMICAL DAMAGE - The invention provides compositions and methods for radioprotection and chemoprevention using therapeutic and prophylactics methods of using (S,S)-SDG (R,R)-SDG, (S,R)-SDG (R,S)-SDG, SDG, SECO, EL, ED, analogs thereof, stereoisomers thereof and other related molecules. | 2020-06-11 |
20200179424 | ANTIMITOSCINS: TARGETED INHIBITORS OF MITOCHONDRIAL BIOGENESIS FOR ERADICATING CANCER STEM CELLS - Antibiotics having intrinsic anti-mitochondrial properties may be chemically modified to target the antibiotics to mitochondria, and the resulting “antimitoscins” may have enhanced anti-cancer properties, among other advantageous properties. Also described are methods for identifying antimitoscins, methods of using antimitoscins to target cancer stem cells, and pharmaceutical compositions for treating cancer containing one or more antimitoscins as the active ingredient. Specific antimitoscins compounds and groups of antimitoscins are also disclosed. | 2020-06-11 |
20200179425 | COMPOSITION FOR PREVENTING HAIR LOSS OR PROMOTING HAIR GROWTH - The present invention is about composition for preventing hair loss or promoting hair growth comprising indirubin derivatives; and one or more selected from the group consisting of Euodia daniellii extract, Persicaria hydropiper extract, Hovenia dulcis extract, methyl vanillate, hesperidin and quercitrin; as an active ingredient. | 2020-06-11 |
20200179426 | METHODS OF USE FOR OENOTHEIN A AND B FROM EPILOBIUM SPECIES - The invention provides medicaments comprising an oenothein, including oral formulations to treat inflammation or to treat hormone balance in perimenopausal, menopausal and postmenopausal women. The oenothein for use in such formulations, such as oenothein A and oenothein B, maybe purified from natural sources, such as | 2020-06-11 |
20200179427 | DOSING SCHEDULE FOR TESETAXEL AND CAPECITABINE - The present disclosure provides methods for treating a patient with cancer, such as metastatic breast cancer, comprising administering tesetaxel and capecitabine to the patient. | 2020-06-11 |
20200179428 | CYCLIC PHOSPHATE SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES - The present invention relates to Cyclic Phosphate Substituted Nucleoside Derivatives of Formula (I), and pharmaceutically acceptable salts thereof, wherein A, B, Q, V, R | 2020-06-11 |
20200179429 | COMPOSITIONS AND METHODS FOR TREATING DEPRESSION - Disclosed is a therapeutic regimen which includes S-adenosyl methionine, or a salt thereof; folic acid, or a metabolite therof, or a salt thereof; and a compound of Formula (I), or salt thereof, useful in the treatment of a variety of conditions, e.g., neuropsychiatric conditions such as depression. The therapeutic regimen may be used in combination with therapeutic agents as described here. | 2020-06-11 |
20200179430 | USE OF P2Y1 RECEPTOR AND ANTAGONIST THEREOF IN PREVENTION AND TREATMENT OF DEPRESSION AND/OR ANXIETY DISORDER - P2Y1 receptor and an antagonist thereof are used in anti-depression and/or anti-anxiety disorder. It has been verified through experimental studies that the P2Y1 receptor can be used for screening for a medicine of anti-depression and/or anti-anxiety disorder, and also used for screening for depression and/or anxiety disorder, and for early warning of depression and/or anxiety disorder; and the antagonist of P2Y1 receptor has anti-depression and anti-anxiety effects which can be used to prepare a medicine of anti-depression and/or anti-anxiety disorder. | 2020-06-11 |
20200179431 | COMPOSITIONS AND METHODS FOR ACTIVATING "STIMULATOR OF INTERFERON GENE" - DEPENDENT SIGNALLING - The present invention provides highly active cyclic-di-nucleotide (CDN) immune stimulators that activate DCs via a recently discovered cytoplasmic receptor known as STING (Stimulator of Interferon Genes). In particular, the CDNs of the present invention are provided in the form of a composition comprising one or more cyclic purine dinucleotides induce human STING-dependent type I interferon production, wherein the cyclic purine dinucleotides present in the composition are 2′-fluoro substituted, bis-3′,5′ CDNs, and most preferably one or more 2′,2″-diF-Rp,Rp, bis-3′,5′CDNs. | 2020-06-11 |
20200179432 | DOUBLE-STRANDED OLIGO RNA STRUCTURE COMPRISING miRNA - The present invention relates to a double-stranded oligo RNA structure comprising double-stranded miRNA, and a composition for preventing or treating cancer, containing the same. More specifically, the present invention relates to an anti-cancer pharmaceutical composition, containing: a double-stranded oligo RNA structure comprising miR-3670, miR-4477 | 2020-06-11 |
20200179433 | Nucleotide, Polypeptide and Applications Thereof - Provided are applications of an upstream Open Reading Frame (uORF) of a Phosphatase and Tensin homolog (PTEN) gene and a polypeptide coded by the same. A potential ORF of 96 bases (31aa-uORF) existing in the 5′ UTR of the PTEN can code an oligopeptide of 31 amino acids (named PTEN-31aa) and plays an important role in the development and progression process of tumors. Provided is a new diagnostic and therapeutic method and a drug screening platform for PTEN expression regulation related diseases, in particular gliomas. Also provided is a polypeptide for treatment of PTEN expression regulation related diseases. | 2020-06-11 |
20200179434 | CRANBERRY-DERIVED COMPOSITIONS FOR POTENTIATING ANTIBIOTIC EFFICACY AGAINST BACTERIAL PERSISTENCE - The present invention provides compositions derived from cranberry including xyloglucan and pectic oligosaccharides, and iridoid terpene glycosides. These compositions can be used in conjunction with antibiotics to synergistically kill bacterial persister cells and inhibit bacterial quiescent phenotypes, thereby improving treatment outcomes in recurrent and other infections. | 2020-06-11 |
20200179435 | MODULATORS OF FOXP3 EXPRESSION - The present embodiments provide methods, compounds, and compositions useful for inhibiting FOXP3 expression, which may be useful for treating, preventing, or ameliorating cancer. | 2020-06-11 |
20200179436 | BRAIN FUNCTION-IMPROVING AGENT, FOOD, AND MEDICINE USING LIPOPOLYSACCHARIDE - A readily-available brain function-improving agent or food composition having an Aβ intracerebral deposition suppressing effect or a learning function-improving effect is provided based on finding, as a result of orally administering | 2020-06-11 |
20200179437 | METHODS OF TREATING CHRONIC WOUNDS USING ELECTROSPUN FIBERS - A method of treating a chronic wound may comprise applying to the wound a first scaffold comprising an electrospun polymer fiber. The electrospun fiber may comprise a polymer selected from the group consisting of polyglycolic acid, poly(lactide-co-caprolactone), polylactic acid, polycaprolactone, copolymers thereof, and combinations thereof. The first scaffold may have a thickness from about 50 μm to about 1 mm, a length from about 1 cm to about 20 cm, and a width from about 1 cm to about 15 cm. The method may further comprise keeping the first scaffold on the chronic wound for a time period of about 3 days to about 21 days. After the time period passes, the chronic wound may have a decreased planimetric area. | 2020-06-11 |
20200179438 | BLOOD GLUCOSE SPIKE SUPPRESSOR, FOOD PRODUCT, AND METHOD FOR PRODUCING BLOOD GLUCOSE SPIKE SUPPRESSOR - A method for producing a blood glucose spike suppressor includes preparing a culture solution containing bacteria capable of accumulating poly(R)-3-hydroxybutyric acid therein, recovering a residue containing granules of poly(R)-3-hydroxybutyric acid by performing a solid-liquid separation on the culture solution, and generating a powder of poly(R)-3-hydroxybutyric acid by drying the residue. | 2020-06-11 |
20200179439 | DRUG AND PRODUCTION METHOD THEREFOR - One drug (solid preparation) | 2020-06-11 |
20200179440 | THIOL AND DISULFIDE-CONTAINING AGENTS FOR INCREASING MEIBOMIAN GLAND LIPID SECRETION - Described herein are compositions and methods for the increasing the quantity of lipids secreted from meibomian glands. Such compositions and methods are useful for the treatment of meibomian gland dysfunction and disorders resulting therefrom. | 2020-06-11 |
20200179441 | SYNERGISTIC COMPOSITIONS FOR INCREASING MITOCHONDRIAL FUNCTION AND ENERGY - The present invention provides a composition or kit that dissolves in water to produce hydrogen rich water for use in increasing mitochondrial function and energy production. The composition or kit contains magnesium metal, i.e., elemental magnesium, an edible acid and either pyrroloquinoline quinone (PQQ) in any of its forms, a NAD+ precursor such as nicotinamide mononucleotide or nicotinamide riboside or a combination thereof. In water, the magnesium metal and edible acid react to produce magnesium ions and H2, which dissolves in the water. | 2020-06-11 |
20200179442 | COLON LAVAGE SYSTEM - The present invention provides compositions, systems, kits, and methods for preparation prior to a colonoscopy or other gastrointestinal procedure. In particular, the present invention provides a colon lavage system comprising an aqueous portion and a solid portion. | 2020-06-11 |
20200179443 | COLONOSCOPY - PREPARATION - The invention provides a colon cleansing solution comprising: a) 300 to 2000 mmol per litre ascorbate anion provided by ascorbic acid, one or more salts of ascorbic acid, or a mixture thereof; and b) 10 to 200 g per litre polyethylene glycol. The invention also provides methods and kits associated with, or making use of the solutions. The invention also provides a method of cleansing the colon of a subject comprising: —administering to the subject an effect amount of a first cleansing solution; and then after a time interval—administering to the subject an effective amount of a second cleansing solution, wherein the two cleansing solutions are as described in the specification. | 2020-06-11 |
20200179444 | COLONOSCOPY - PREPARATION - The invention provides a colon cleansing solution comprising: a) 300 to 2000 mmol per litre ascorbate anion provided by ascorbic acid, one or more salts of ascorbic acid, or a mixture thereof; and b) 10 to 200 g per litre polyethylene glycol. The invention also provides methods and kits associated with, or making use of the solutions. The invention also provides a method of cleansing the colon of a subject comprising: —administering to the subject an effect amount of a first cleansing solution; and then after a time interval —administering to the subject an effective amount of a second cleansing solution, wherein the two cleansing solutions are as described in the specification. | 2020-06-11 |
20200179445 | ANTIMICROBIAL COMPOSITION COMPRISING A POLYSACCHARIDE, A STABILIZING AGENT AND TRIIODIDE, METHOD OF PREPARATION THEREOF AND USE THEREOF - A composition having antimicrobial activity is provided. The composition comprises a polysaccharide, a stabilizer, and a triiodide, where the triiodide decomposition to iodide and volatile iodine can be significantly suppressed by the presence of the stabilizer. Methods of preparing and using the composition and devices prepared therewith are also disclosed. As compared to liquid forms comprising triiodide, stabilized solid forms can be used for a much wider range of applications due to their shape stability and a significantly smaller volume and weight of total material. | 2020-06-11 |
20200179446 | METHODS AND TREATMENT OF TRAUMA - Methods for the reversal of hemorrhagic shock or hemorrhagic trauma. | 2020-06-11 |
20200179447 | AUTOLOGOUS IRRADIATED WHOLE CELL TUMOR VACCINES LENTIVIRALLY ENGINEERED TO EXPRESS CD80, IL-15 AND IL-15 RECEPTOR ALPHA - Provided herein, inter alia, are cell media compositions and whole cell vaccines comprising recombinant cells expressing IL-15, IL-15Rα, and CD80 capable of treating and preventing relapse in individuals diagnosed with or thought to have leukemia as well as methods for using the same. | 2020-06-11 |
20200179448 | METHODS AND COMPOSITIONS INVOLVING INTERLEUKIN-6 RECEPTOR ALPHA-BINDING SINGLE CHAIN VARIABLE FRAGMENTS - Disclosed are compositions comprising an isolated chimeric interleukin 6 receptor alpha (IL-6Rα) binding protein or cells expressing an isolated chimeric IL-6Rα binding protein. The isolated IL-6Rα chimeric binding protein and cells expressing the protein may be used in methods of treating cancer and reducing the risk of cytokine release syndrome. | 2020-06-11 |
20200179449 | METHODS FOR GENERATING POLYCLONAL REGULATORY T CELLS - The present disclosure provides for methods to produce B cell-expanded Tregs that are more stable and more effective than donor-specific Tregs for suppressing polyclonally activated T cells. In certain embodiments, the present polyclonal Tregs can react to many donors, not just a specific donor. | 2020-06-11 |
20200179450 | T-CELL ANTIGEN TARGETED CHIMERIC ANTIGEN RECEPTOR (CAR) AND USES IN CELL THERAPIES - This disclosure relates to engineered cells, such as T-cells, comprising targeted chimeric antigen receptors. In certain embodiments, T-cell targeted chimeric antigen receptors (CAR) are expressed at higher levels when endogenous expression of a T-cell antigen is knocked-down or reduced in the T-cells. In certain embodiments, the engineered cells are immunoregulatory cells genetically modified to prevent or reduce T-cell antigen expression, or the immunoregulatory cells contain a nucleic acid that reduces or knocksdown T-cell mRNA expression, under conditions such that reduced expression of the T-cell antigen results in an increased expression of a chimeric antigen receptor compared to similarly situated immunoregulatory cells wherein the expression of the T-cell antigen is not altered or reduced. In certain embodiments, T-cell antigens include, but are not limited to, CD5, CD7 and CD3. | 2020-06-11 |
20200179451 | COMPOSITIONS AND METHODS FOR IMMUNE CELL MODULATION IN ADOPTIVE IMMUNOTHERAPIES - Compounds that either produce a higher proportion or greater absolute number of phenotypically identified naive, stem cell memory, central memory T cells, adaptive NK cells, and type I NKT cells are identified. Compositions and methods for modulating immune cells including T, NK, and NKT cells for adoptive cell therapies, such as those providing improvements in one or more therapeutic outcomes, are provided. | 2020-06-11 |
20200179452 | ENABLING CHOLESTEROL CATABOLISM IN HUMAN CELLS - Compositions, methods, and systems for modifying sterol metabolism in a subject is disclosed. In some embodiments, the subjects may be administered one or more mammalian cells modified to express at least one sterol degrading enzyme derived from a bacterium. In many embodiments, the cell is a macrophage or monocyte stably expressing three or more enzymes that aid in opening the β ring of cholesterol. The disclosed compositions and methods may be useful in lowering cholesterol levels in a subject in need thereof. In some embodiments, the subject may have a genetic predisposition to atherosclerosis. | 2020-06-11 |
20200179453 | PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS - The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. | 2020-06-11 |
20200179454 | PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS - The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. | 2020-06-11 |
20200179455 | PLATELET RICH PLASMA FORMULATIONS AND USE THEREOF - Compositions for platelet rich plasma (PRP), depleted in neutrophils, are provided. Generally, these compositions comprise a higher concentration of platelets, lymphocytes and monocytes than whole blood with selective depletion of neutrophils to a concentration of less than about 5000/μl. These compositions may have depressed concentrations of red blood cells and hemoglobin. In some variations, the compositions may be useful to treat damaged connective tissue and/or to slow or stop cardiac apoptosis after a heart attack. The PRP composition may be delivered in conjunction with reperfusion therapy. | 2020-06-11 |
20200179456 | CELL PREPARATIONS FOR EXTEMPORANEOUS USE, USEFUL FOR HEALING AND REJUVENATION IN VIVO - The present invention relates to new plasma or new platelet-rich plasma preparations, new cell dissociation methods, new cell associations or compositions, a method of preparation thereof, a use thereof, devices for the preparation thereof and preparations containing such a platelet-rich plasma preparation and cell associations or compositions. Specifically, the invention provides plasma or platelet-rich plasma alone or in cell composition preparations for use in tissue regeneration and bone regeneration and pain reduction. | 2020-06-11 |
20200179458 | MICROORGANISMS FOR USE AND DELIVERY TO THE RESPIRATORY SYSTEM - Preparations comprising microorganisms for delivery as a plurality of particles, kits including microorganism preparations for delivery as a plurality of particles, and devices for administering microorganism preparations as a plurality of particles are provided. Methods of administering microorganisms via nebulization or inhalation are provided. Methods of introducing microorganisms to the respiratory system are provided. Methods of treating disorders, including respiratory disorders and inflammatory disorders, with preparations comprising microorganisms are provided. | 2020-06-11 |